Affiliation:
1. Tutor, Department Of Pharmacology, Kilpauk Medical College
2. Professor, Department Of Diabetology, Stanley Medical College
Abstract
Aim of this study to establish the safety and efcacy of empagliozin. It's a Longitudinal observational study conducted in Medical college on 140
Type 2 Diabetes patients. The patients who where already in other OADs and started to take Empagliozin 25mg within one week of initiation was
taken into the study. The baseline value of FBS, PPBS, Weight, LDL, HDL, Sr.Electrolytes was noted. The patients will be followed up in 1st , 3rd ,
6th month in each follow up visit physical examination will be done and clinical characteristic regarding adverse effects are noted. The laboratory
investigations are repeated at the end of 6th month.The results are mean reduction in FBS & PPBS at the end of 6th month are 43mg/dl and 47mg/dl
respectively. On observing the adverse events the incidence of hypoglycemia is 4.2%, hyponatremia is 7.5%, hypokalemia is 2.1% and Urinary
tract infection is 2% . The serious adverse event is observed in one patient with a episode of DKA. There was mild increase in LDL and electrolyte
imbalance. Empagliozin 25mg OD shown better efcacy with lesser side effects.
Subject
Hematology,Molecular Biology,Biochemistry,General Medicine,Anesthesiology and Pain Medicine,Molecular Biology,Biochemistry,Applied Mathematics,Computer Science Applications,Molecular Biology,Biochemistry,Structural Biology,Biological Psychiatry,Psychiatry and Mental health,Nature and Landscape Conservation,Animal Science and Zoology,Ecology,Nature and Landscape Conservation,Ecology, Evolution, Behavior and Systematics,Health, Toxicology and Mutagenesis,Developmental Biology,Toxicology,Embryology,Developmental Biology,Embryology,General Medicine